Drug Actives from Bench into Market.
Home About Girindus Capabilities Investor Relations Join us Events Contact us Sitemap
Deutsch
IR
Investor Relations
News
Corporate Calendar
IR Contacts
Financial Reports
Shareholder Meeting
Capital Increase IV
Archive
Factsheet
Stock Quote

Girindus  AG  –  applies  for  change  of  segment

27.09.05 —

Bensberg, September 27, 2005 – Girindus AG, a company listed in the Prime Segment of the German Stock Exchange and specialized in process development and the production of innovative drug and cosmetic actives, has applied to change from the Prime Standard to the General Standard.

Now that Solvay Organics GmbH holds almost 75% of Girindus' shares after its public takeover offer, Girindus AG's Management Board today applied for revocation of its admission to the segment of the regulated market with additional admission obligations ("Prime Standard") with effect to December 31, 2005. This will not affect the company's admission to trading in the regulated market (General Standard).

For further information, contact:

Peter J. Bergsteiner,
Director Finance & Investor Relations
Girindus AG, 51402 Bensberg
T: +49 – (0)2204 – 926 - 90
F: +49 – (0)2204 – 926 - 990
pbergsteiner@girindus.com

top

                                                                                                                                                                                                                                                                                                                                                                                               

Girindus AG – konkretisiert Ergebniserwartung für das laufende Jahr – Hauptaktionär sichert Reserven
(21.12.07)

Bensberg, den 08. November 2007 – Die Girindus AG, Verfahrensentwickler und Wirkstoffproduzent für innovative Arzneimittel und Kosmetika, teilt mit, dass alle öffentlichen Informationen über einen Gr
(08.11.07)

Girindus AG – beruft neuen Finanzvorstand
(17.10.07)

Girindus AG – Veränderungen im Vorstand
(27.09.07)

Girindus AG – Ad hoc
(01.08.07)

Girindus AG – Ad hoc
(13.04.07)

Girindus AG – Ad hoc
(05.04.07)

Girindus AG – Ad hoc
(29.03.07)

Girindus AG – Ad hoc
(15.02.07)

Girindus AG – Ad hoc
(26.10.06)

Girindus AG – Ad hoc
(11.08.06)

Girindus AG - Oligonucleotide Production Expansion Accelerated
(14.06.06)

Girindus AG – Solvay Beteiligung erreicht 75%
(13.06.06)

Girindus AG – Targets for 2005 corrected - New majority shareholder secures growth financing
(20.10.05)

Girindus AG – Girindus informs the Governor of the State of Ohio, Bob Taft, about the latest developments
(19.10.05)

Girindus AG strengthens its Management Board by appointing Dr. Harald Mothes
(05.10.05)

Girindus AG – Change to Supervisory Board
(30.09.05)

Girindus AG – applies for change of segment
(27.09.05)

Girindus AG - Changes within management board and supervisory board
(31.08.05)

Girindus AG – Solvay plans takeover of Girindus AG
(22.06.05)

Girindus AG - Erste Vertragsverhandlungen bestätigen Blockbusterpotential für GirLiteTM dA 100
(12.05.05)

Girindus AG – False Accusations Made By Animal Conservationists
(05.04.05)

Girindus AG signs option agreement for an exclusive in-license of a new active ingredient
(29.03.05)

Girindus AG – präsentiert den Jahresabschluss 2004 und stellt den Ausblick für die kommenden Jahre vor
(29.03.05)

Oligonucleotide Symposium – An Outstanding Success
(15.03.05)